Sugi Predict

Sugi Predict / Compounds / SCHEMBL2062991

SCHEMBL2062991

SCHEMBL2062991

CC(C)(C)OC(=O)N[C@@H](CCBr)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 7/20 0.49
▸ CTSS P25774 6/20 0.49
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PPARA Q07869 7/20 0.46
▸ PPARG P37231 6/20 0.46
▸ CTSL P07711 1/20 0.46
▸ CTSB P07858 1/20 0.46
▸ ACE P12821 1/20 0.45
▸ PPARD Q03181 2/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ IDO1 P14902 1/20 0.42
▸ ITGB3 P05106 1/20 0.42
▸ ITGA2B P08514 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3783892 1.00 CTSK (0.49) CTSKCTSSMEN1GAAKMT2A
SCHEMBL2062994 1.00 CTSK (0.49) CTSKCTSSMEN1GAAKMT2A
SCHEMBL3378213 0.90 CTSK (0.51) CTSKCTSSMEN1GAAKMT2A
SCHEMBL3570961 0.90 CTSK (0.51) CTSKCTSSMEN1GAAKMT2A
SCHEMBL3585273 0.90 CTSK (0.51) CTSKCTSSMEN1GAAKMT2A
SCHEMBL1162230 0.89 CTSK (0.50) CTSKCTSSMEN1GAAKMT2A
SCHEMBL27604122 0.89 CTSK (0.50) CTSKCTSSMEN1GAAKMT2A
SCHEMBL16339562 0.87 CTSK (0.49) CTSKCTSSMEN1GAAKMT2A
SCHEMBL16339563 0.87 CTSK (0.49) CTSKCTSSMEN1GAAKMT2A
SCHEMBL13422140 0.86 CTSK (0.46) CTSKCTSSMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630291-B9 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-05-29 — — EP disclosed
EP-4374858-A2 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2024-05-29 — — EP disclosed
EP-3630291-B1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-01-10 — — EP disclosed
US-20230019236-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2023-01-19 — — US disclosed
WO-2021127499-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 — — WO disclosed
US-20210147382-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-20 — — US disclosed
US-10954202-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof ABBVIE INC. (US) 2021-03-23 — — US disclosed
US-20210009542-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF ABBVIE INC. 2021-01-14 — — US disclosed
EP-3630291-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2020-04-08 — — EP disclosed
WO-2018215801-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-11-29 — — WO disclosed
WO-2008050096-A1 PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER CHROMA THERAPEUTICS LTD. (GB) 2008-05-02 — — WO disclosed
US-7317040-B2 Antiinflamamtory agents; spesis shock SMITHKLINE BEECHAM CORPORATION (US) 2008-01-08 — — US disclosed
WO-2007129005-A1 AMINOACID DERIVATIVES OF THIAZOLES AS INHIBITORS OF PI3 KINASE CHROMA THERAPEUTICS LTD. (GB) 2007-11-15 — — WO disclosed
EP-1606283-A4 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2007-05-23 — — EP disclosed
EP-1606283-A2 P38 INHIBITORS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2005-12-21 — — EP disclosed
CN-1538951-A Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of chemotaxis of polymorphonucleate and mononucleate cells ��ķ�ɷ����޹�˾ 2004-10-20 — — CN disclosed
WO-2004078116-A2 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. (US) 2004-09-16 — — WO disclosed
US-20040087654-A1 Nitric oxide synthase inhibitor phosphate salt SMITHKLINE BEECHAM CORPORATION 2004-05-06 — — US disclosed
EP-1351929-A1 NITRIC OXIDE SYNTHASE INHIBITOR PHOSPHATE SALT GLAXO GROUP LIMITED (GB) 2003-10-15 — — EP disclosed
WO-2002050021-A1 NITRIC OXIDE SYNTHASE INHIBITOR PHOSPHATE SALT GLAXO GROUP LIMITED (GB) 2002-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019236-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN1, PTPN2, PTPN18 CTSK 3003/4885CTSS 3337/4885MEN1 3734/4885
US-10954202-B2 Protein tyrosine phosphatase inhibitors and methods of use thereof PTPN1, PTPN2, PTPN18 CTSK 3003/4885CTSS 3337/4885MEN1 3734/4885
US-20210147382-A1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 BCL6, BCL6B, BCL3 CTSK 1427/4885CTSS 2371/4885MEN1 727/4885
US-20210009542-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPN1, PTPN2, PTPN18 CTSK 3003/4885CTSS 3337/4885MEN1 3734/4885
US-20040087654-A1 Nitric oxide synthase inhibitor phosphate salt NOS3, NOS1, SLC20A1 CTSK 4081/4885CTSS 2285/4885MEN1 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback